Tissue Regenix Group PLC Gareth Jones commences position as CFO (3969F)

TIDMTRX

RNS Number : 3969F

Tissue Regenix Group PLC

29 October 2018

Tissue Regenix Group plc

Gareth Jones commences position as CFO

Leeds, 29 October 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company today announces that Gareth Jones has officially taken up his post as Chief Financial Officer of the Group.

Mr Jones' appointment was announced on July 4(th) with an expected commencement date of November 30(th) , meaning that Mr Jones will be stepping into post a month earlier than anticipated having completed the handover process in his previous role as CFO at Applied Graphene Materials, plc.

Steve Couldwell, CEO, Tissue Regenix Group commented: "I am delighted to welcome Gareth to the Group. He will play a pivotal role in the strategic direction, focus and acceleration of our commercial success. Utilising his experience and knowledge of both operational and financial enhancement initiatives, alongside his international and listed company experience, we expect Gareth to help execute on our vision and accelerate sustainable long term shareholder value."

For more Information:

 
 Tissue Regenix Group plc                   Tel: 0330 430 3073 / 
  Caitlin Pearson Head of Communications     07920272 441 
-----------------------------------------  --------------------- 
 
 Jefferies International Ltd                Tel: 020 7029 8000 
  Simon Hardy / Christopher Binks 
-----------------------------------------  --------------------- 
 
 FTI Consulting                             Tel: 0203 727 1000 
  Brett Pollard / Mo Noonan/ Mary Whittow 
=========================================  =====================

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL(R) ') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies(R) , a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BOAEAFEPALEPFAF

(END) Dow Jones Newswires

October 29, 2018 03:00 ET (07:00 GMT)

Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2024 to Jun 2024